Targovax and Papyrus Therapeutics enter research collaboration to develop novel ONCOS viruses
OSLO: Targovax ASA has entered into a research collaboration agreement with Papyrus Therapeutics to assess the potential of combining their respective proprietary technology platforms to develop a first-in-class oncolytic virus concept with RTK inhibitor functionality. Papyrus Therapeutics, Inc. (West Chester,…